Document Detail


Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.
MedLine Citation:
PMID:  23340857     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Rituximab (RTX) has recently showed promising results in the treatment of steroid-dependent idiopathic nephrotic syndrome (SDNS).
METHODS: This was a retrospective multicenter study of 18 children treated with RTX for SDNS, with a mean follow-up of 3.2 years. RTX was introduced because of side effects or relapses during therapy with immunosuppressive agents. The children received one to four infusions of RTX during the first course of treatment, and subsequent infusions were given due to CD19-cell recovery (CD19 >1 %; 54 % of children) or relapse (41 %), as well as systematically (5 %).
RESULTS: Treatment with RTX maintained sustained remission without relapse in 22 % of patients and increased the duration of remission in all other patients. The time between two successive relapses was 9 months in the absence of re-treatment and 24.5 months when infusions were performed at the time of CD19-cell recovery. At the last follow-up, 44.5 % of patients were free of oral drug therapy. Of those still receiving oral drugs, all doses had been decreased. No serious adverse events occurred.
CONCLUSION: The results of this retrospective study confirm the efficacy and very good safety of RTX in the treatment of SDNS. The optimal therapeutic protocol seems to be a repeated single infusion at the time of CD19-cell recovery.
Authors:
Stéphanie Tellier; Karine Brochard; Arnaud Garnier; Flavio Bandin; Brigitte Llanas; Vincent Guigonis; Mathilde Cailliez; Christine Pietrement; Olivier Dunand; Sylvie Nathanson; Aurélia Bertholet-Thomas; Lydia Ichay; Stéphane Decramer
Related Documents :
24442987 - Critical incidents related to opioid infusions in children: a five-year review and anal...
23152337 - Surveillance of influenza a h1n1 2009 among school children during 2009 and 2010 in sã...
8254157 - Giardiasis. issues in diagnosis and management.
23382737 - The long-term effectiveness of generic adult fixed-dose combination antiretroviral ther...
20620807 - Obesity in hong kong chinese preschool children: where are all the nurses?
10533997 - Longitudinal follow-up of the intellectual and academic functioning of children receivi...
Publication Detail:
Type:  Journal Article; Multicenter Study     Date:  2013-01-23
Journal Detail:
Title:  Pediatric nephrology (Berlin, Germany)     Volume:  28     ISSN:  1432-198X     ISO Abbreviation:  Pediatr. Nephrol.     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-04-22     Completed Date:  2013-11-13     Revised Date:  2014-03-20    
Medline Journal Info:
Nlm Unique ID:  8708728     Medline TA:  Pediatr Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  911-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal, Murine-Derived / adverse effects,  therapeutic use*
Child
Child, Preschool
Female
Humans
Immunologic Factors / therapeutic use*
Infant
Male
Nephrotic Syndrome / drug therapy*
Retrospective Studies
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Murine-Derived; 0/Immunologic Factors; 0/rituximab
Comments/Corrections
Comment In:
Pediatr Nephrol. 2014 Mar;29(3):491-2   [PMID:  24240472 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney ...
Next Document:  Bandgap broadly tunable GaZnSeAs alloy nanowires.